Opinion
Video
Author(s):
Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.
Hallucinogen-Related ER Visit Linked to Increased Schizophrenia Risk
Introducing Medical Ethics Unpacked, with Dominic Sisti, PhD, and Steve Levine, MD
Emraclidine Fails to Significantly Reduce Schizophrenia Symptoms in Phase 2 EMPOWER Trials
The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC
Phase 3 Data Shows Lumateperone Delays Schizophrenia Relapse Longer Than Placebo
Phase 3 Data Shows TEV-‘749 Injection Improves Social Function in Schizophrenia